Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients

Pharmacogenomics

Volumn 14, Issue 13, 2013, Pages 1605-1613

  Ferraresso, Mariano ^a,b   Belingheri, Mirco ^c   Turolo, Stefano ^c   Ghio, Luciana ^c   Tirelli, Amedea Silvia ^c   Grillo, Paolo ^c   Lepore, Marta ^c   Edefonti, Alberto ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b St Joseph Hospital   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

ABCB1; cyclosporine; developmental pharmacology; pediatric kidney transplantation; pharmacogenetic; pharmacokinetic; single nucleotide polymorphism; SXR

Indexed keywords

ALANINE; CYCLOSPORIN; CYSTEINE; GLYCINE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THREONINE;

ABCB1 GENE; ADULT; AGE; ARTICLE; CHILD; CHILD DEVELOPMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; FEMALE; FOLLOW UP; GENE; GENE DELETION; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MALE; PRESCHOOL CHILD; PROMOTER REGION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SXR GENE;

ADOLESCENT; ADULT; ALLELES; CHILD; CYCLOSPORINE; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECEPTORS, STEROID; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84885409158     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.148     Document Type: Article

References (48)

1. Meier-Kriesche HU, Li S, Gruessner RW et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am. J. Transplant. 6(5 Pt 2), 1111-1131 (2006).
2. Marks SD. How have the past 5 years of research changed clinical practice in paediatric nephrology? Arch. Dis. Child. 92(4), 357-361 (2007).
3. Kovarik JM, Mueller EA, Richard F et al. Evidence for earlier stabilization of cyclosporine pharmacokinetics in De novo renal transplant patients receiving a microemulsion formulation. Transplantation 62(6), 759-763 (1996).
4. Keown P, Landsberg D, Halloran P et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 62(12), 1744-1752 (1996).
5. Barone G, Bunke CM, Choc MG et al. Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group. Transplant. Proc. 28(4), 2183-2186 (1996).
6. Del Mar Fernández De Gatta M, Santos-Buelga D, Domínguez-Gil A, García MJ. Immunosuppressive therapy for paediatric transplant patients: Pharmacokinetic considerations. Clin. Pharmacokinet. 41(2), 115-135 (2002).
7. Matas AJ, Gillingham KJ, Chavers BM et al. The importance of early cyclosporine levels in pediatric kidney transplantation. Clin. Transplant. 10(6 Pt 1), 482-486 (1996).
8. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 40(3), 159-168 (2001).
9. Dai Y, Iwanaga K, Lin YS et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem. Pharmacol. 68(9), 1889-1902 (2004).
10. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268(9), 6077-6080 (1993).
11. Hesselink DA, Van Schaik RH, Van Der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3), 245-254 (2003).
12. Anglicheau D, Thervet E, Etienne I et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther. 75(5), 422-433 (2004).
13. Thervet E, Anglicheau D, Legendre C, Beaune P. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther. Drug Monit. 30(2), 143-150 (2008).
14. Eng HS, Mohamed Z, Calne R et al. The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int. 69(10), 1858-1864 (2006).
15. Hesselink DA, Van Gelder T, Van Schaik RH. The pharmacogenetics of calcineurin inhibitors: One step closer toward individualized immunosuppression? Pharmacogenomics 6(4), 323-337 (2005).
16. Liu Y, Ji W, Yin Y et al. The effects of splicing variant of PXR PAR-2 on CYP3A4 and MDR1 mRNA expressions. Clin. Chim. Acta 403(1-2), 142-144 (2009).
17. Zhou C, Verma S, Blumberg B. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl. Recept. Signal 7, e001 (2009).
18. Gosden RG, Feinberg AP. Genetics and epigenetics-nature?s pen-and-pencil set. N. Engl. J. Med. 356(7), 731-733 (2007).
19. Wong AH, Gottesman II, Petronis A. Phenotypic differences in genetically identical organisms: The epigenetic perspective. Hum. Mol. Genet. 14(Spec. No. 1), R11-R18 (2005).
20. Stevens JC, Hines RN, Gu C et al. Developmental expression of the major human hepatic CYP3A enzymes. J. Pharmacol. Exp. Ther. 307(2), 573-582 (2003).
21. Miki Y, Suzuki T, Tazawa C, Blumberg B, Sasano H. Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol. Cell. Endocrinol. 231(1-2), 75-85 (2005).
22. Turolo S, Tirelli AS, Ferraresso M et al. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol. Rep. 62(6), 1159-1169 (2010).
23. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42(1), 121-130 (1986).
24. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349(12), 1157-1167 (2003).
25. Michaud J, Dubé P, Naud J et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br. J. Pharmacol. 144(8), 1067-1077 (2005).
26. Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab. Dispos. 32(11), 1239-1246 (2004).
27. Nolin TD, Appiah K, Kendrick SA, Le P, Mcmonagle E, Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J. Am. Soc. Nephrol. 17(9), 2363-2367 (2006).
28. Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab. Dispos. 36(1), 124-128 (2008).
29. Fanta S, Jönsson S, Backman JT, Karlsson MO, Hoppu K. Developmental pharmacokinetics of ciclosporin-A population pharmacokinetic study in paediatric renal transplant candidates. Br. J. Clin. Pharmacol. 64(6), 772-784 (2007).
30. Ushijima K, Uemura O, Yamada T. Age effect on whole blood cyclosporine concentrations following oral administration in children with nephrotic syndrome. Eur. J. Pediatr. 171(4), 663-668 (2012).
31. Sakaeda T, Iijima K, Nozu K et al. Prediction of systemic exposure to cyclosporine in Japanese pediatric patients. J. Hum. Genet. 51(11), 969-976 (2006).
32. Whitington PF, Emond JC, Whitington SH, Broelsch CE, Baker AL. Small-bowel length and the dose of cyclosporine in children after liver transplantation. N. Engl. J. Med. 322(11), 733-738 (1990).
33. Dunn S. Neoral use in the pediatric transplant recipient. Transplant. Proc. 32(Suppl. 3A), S20-S26 (2000).
34. Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin. Pharmacokinet. 32(6), 481-495 (1997).
35. Takahashi H, Ishikawa S, Nomoto S et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin. Pharmacol. Ther. 68(5), 541-555 (2000).
36. De Wildt SN, Kearns GL, Sie SD, Hop WC, Van Den Anker JN. Pharmacodynamics of intravenous and oral midazolam in preterm infants. Clin. Drug Investig. 23(1), 27-38 (2003).
37. Marshall J, Rodarte A, Blumer J, Khoo KC, Akbari B, Kearns G. Pediatric pharmacodynamics of midazolam oral syrup. Pediatric Pharmacology Research Unit Network. J. Clin. Pharmacol. 40(6), 578-589 (2000).
38. Noda T, Todani T, Watanabe Y, Yamamoto S. Liver volume in children measured by computed tomography. Pediatr. Radiol. 27(3), 250-252 (1997).
39. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: A meta-analysis. Liver Transpl. 11(12), 1481-1493 (2005).
40. Björkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: Theophylline and midazolam as model drugs. Br. J. Clin. Pharmacol. 59(6), 691-704 (2005).
41. Fanta S, Niemi M, Jönsson S et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet. Genomics 18(2), 77-90 (2008).
42. Crettol S, Venetz JP, Fontana M et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet. Genomics 18(4), 307-315 (2008).
43. Fanta S, Jönsson S, Karlsson MO et al. Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: Evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism. J. Clin. Pharmacol. 50(5), 581-597 (2010).
44. Ferraresso M, Turolo S, Belinghieri M et al. The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients. Pediatr. Transplant. 16(6), 658-663 (2012).
45. Bai S, Liu J, Lu SK, Brunner LJ. In vivo induction of hepatic P-glycoprotein by cyclosporine in the rat. Res. Commun. Mol. Pathol. Pharmacol. 109(1-2), 103-114 (2001).
46. Hauser IA, Koziolek M, Hopfer U, Thévenod F. Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells. Kidney Int. 54(4), 1139-1149 (1998).
47. Jetté L, Beaulieu E, Leclerc JM, Béliveau R. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am. J. Physiol. 270(5 Pt 2), F756-F765 (1996).
48. Gallagher WM, Tweats D, Koenig J. Omic profiling for drug safety assessment: Current trends and public-private partnerships. Drug Discov. Today 14(7-8), 337-342 (2009).